[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"brand-jingfengzhiyao":3},{"head":4,"company":39,"invest":44,"children":45,"shops":46,"category":47,"sameIndustry":5,"rid":6},{"createTime":5,"updateTime":5,"createBy":5,"updateBy":5,"brandId":6,"brandLogo":7,"brandImage":5,"brandName":8,"webName":9,"balias":5,"enterId":10,"mainindustry":11,"industry":5,"brandType":12,"brandHonor":5,"brandTel":13,"establishdate":5,"brandBirth":14,"cityarea":5,"brandWebsite":5,"brandSobp":5,"brandVisit":5,"totalVisits":15,"status":16,"isDeleted":16,"comment":5,"remark":5,"logoExistStatus":17,"imageExistStatus":17,"industryId":5,"industryRanking":5,"score":5,"enterName":18,"mallShopList":19,"brandSummary":5,"likes":5,"unlikes":5,"follow":5,"pagetitle":20,"pagekeywords":21,"pagedesc":22,"brandContent":23,"province":5,"city":5,"area":5,"detailaddress":24,"unifiedscc":25,"enterType":26,"enterLegalperson":27,"enterStablishdate":28,"regauthority":29,"licenseValidity":30,"approvaldate":31,"regcapital":32,"incapital":33,"businessscope":34,"ownBrand":5,"enterTelphone":35,"enterWebsite":36,"business":37,"enterQq":5,"enterMail":38,"bindUser":5,"enterMployeenum":5,"regcapitalunit":5,"abnormal":5,"yeartax":5,"regtrademark":5},null,"47232","\u002Fprofile\u002Fupload\u002F2025\u002F01\u002F25\u002F540e3f6307cf68c9c95d6ee09ac14a2e.gif","景峰制药","jingfengzhiyao",40608,3244,3,"021-66861001","岳阳市",316,0,"1","湖南景峰医药股份有限公司",[],"景峰制药品牌简介_景峰药品_景峰医药→品牌之家","景峰医药,景峰制药,景峰中药,景峰化学药,景峰生物药","景峰制药品牌简介，品牌之家为您推荐景峰医药品牌历程、产品价格、口碑评价等内容。","湖南景峰医药股份有限公司于2014年12月上市，公司秉承“夯实基础、技术创新、持续发展”的理念，坚持走与国际接轨的特色仿创药产业化道路。现拥有22家全资、控股子公司分布在上海、贵州、辽宁、江苏和海南等地。\n\n公司主营业务产品涵盖了心脑血管、肿瘤、骨科、儿科、妇科等重大疾病领域，拥有“佰塞通参芎葡萄糖注射液”、“金港榄香烯乳状注射液”、“佰备玻璃酸钠注射液”、“盐酸替罗非班氯化钠注射液”等核心大品种，“心脑宁胶囊”、“儿童回春颗粒”、“通迪胶囊”、“乐脉丸”等特色中药产品，以及“注射用兰索拉唑”、“注射用奥美拉唑钠”、“注射用泮托拉唑钠”、“注射用盐酸吉西他滨”、“注射用培美曲塞二钠”、“盐酸伊立替康注射液”、”注射用奥沙利铂”、“注射用磷酸氟达拉滨”、“注射用单磷酸阿糖腺苷”和“注射用克林霉素磷酸酯”等产品。\n\n上海景峰制药有限公司为景峰医药（000908.SZ）全资子公司，成立于2003年，注册资金7.71亿元。主要开展化学药、生物制剂等产品研发和生产。目前公司的主营产品为玻璃酸钠注射液（骨科及外科用），凭借着品种及规格优势，在同类产品中保持较强的销量。\n\n上海景峰是一家以创新生物药和化学药为核心，首仿药为主流，简单仿制药为补充的国际化、高技术、高附加值的医药制造企业。“化学1类”新药JZC11注射液作为玻璃酸钠注射液的升级产品，已获得国家药监局临床批件，在后续的临床试验及上市推广中可直接受益现有的市场基础。公司在研项目丰富，加大抗肿瘤和心血管用药领域的药品研发力度，不断充实产品储备，加速我国肿瘤药的原研替代，真正造福百姓。\n\n“以人才为本，崇尚技术”是公司战略发展的核心驱动力，公司引进年轻的博士硕士为各项目核心人员，为公司的质量、生产、研发的发展，奠定坚实的基础。公司计划在仿制药、生物药、原料药和注射剂方面的研发投入超过10亿元，其中投资1.5亿修建的生物药车间已于2018年竣工，未来年产值预计可达40个亿。","湖南省常德经济技术开发区樟木桥街道双岗社区桃林路661号（双创大厦1703室））","914306007121062680","其他股份有限公司(上市)","杨栋","1998-12-18","岳阳市市场监督管理局","-","2024-11-14","87,977.4351万(元)","19,000.12万(元)","以自有资产进行医药、医疗项目投资；生物制药技术项目的研发与投资；商品进出口贸易；企业管理咨询、医疗医药研发技术咨询。（依法须经批准的项目，经相关部门批准后方可开展经营活动）","0736-7320908","www.jfyiyao.com","医药制造业","ir@jfzhiyao.com",{"enterId":40,"enterName":18,"province":5,"city":5,"area":5,"detailaddress":24,"unifiedscc":25,"enterType":26,"enterLegalperson":27,"enterStablishdate":28,"regauthority":29,"licenseValidity":30,"approvaldate":31,"regcapital":32,"incapital":33,"businessscope":34,"ownBrand":5,"enterTelphone":35,"enterWebsite":36,"business":37,"performance":41,"socialSecurity":42,"registrationNumber":43,"enterQq":5,"enterMail":38,"bindUser":5,"enterMployeenum":5,"regcapitalunit":5,"abnormal":5,"yeartax":5,"status":16,"regtrademark":5,"remark":5},"40608","开业","17人","430000000002121",{"createTime":5,"updateTime":5,"createBy":5,"updateBy":5,"id":5,"brandId":5,"brandName":5,"busmodel":5,"franchiseFund":5,"totalStores":5,"devmodel":5,"franchiseIndustry":5,"investmenttel":5,"suitablePeople":5,"state":5},[],[],[]]